information consumer product safety improvement act authorized distributors of record product approval timeline research pipeline clinical trials investigator sponsored research responsibility csr report 2015 u.s. patient access developing world access corporate contributions policy perspectives gilead foundation state disclosures news press releases company statements events media faqs fact sheets and infographics media inquiries investors recent news corporate governance stock information financial information earnings sec filings shareholder center annual reports e mail alerts investor faqs investor contacts investor disclaimer careers research pipeline our values developing world access corporate responsibility u.s. benefits learn how gilead made a positive impact around the world in 2015 . find out how gilead transforms and simplifies care for people with life threatening illnesses worldwide . video link online annual review read transcript title slide gilead makes an impact on every stage of the continuum of care from the laboratory to the clinic to access to medicines in all corners of the world . we asked our employees what that means to them . shawn lichaa one of the great joys of working at gilead is that all day i m talking to some of the most brilliant minds from scientists to lawyers to marketing people . and we re all focused on one thing . we re focused on the patients and how the patient is going to be impacted by our work . gennyne walker and while we re working on the development of one drug we re already thinking about three or four other drugs down the line that might be better than the current drug that we re developing . masaaki hiroi in japanese i wanted to work at gilead not only because i lost my mother when i was young but because i wanted to eliminate one life threatening disease from this world . david dornan gilead s commitment to oncology i think really is ... it s is very similar to what it was in virology . and the organization is committed to doing the same thing by building on science foundation blocks and applying what our knowledge and expertise are to solve the problem . molly walker my mom has cll and it s really important to me to to be that gilead is working on cll as a therapeutic area . and it s great for me to be able to learn about the disease and you know talk to my mom about it . and my mom is so proud . angela opoku i m from west african descent . i ve been to ghana a couple of times and i ve seen first hand how hiv has affected lives there . we ve been a market leader for many many years . and to be able to be part of that success story is really what drove me here . louisa leung one of the key projects i ve been working on recently is to really help folks understand why it s so important to have broad access to hiv and hcv therapies and that ultimately that provides long term benefit not only to the patient but to the community and to society at large . betty chiang 70 percent of patients with hepatitis c are actually from africa and southeast asia and latin america . i m hoping that with gilead s innovative product in hepatitis c we re able to bring it to the countries that need it the most . arnaud dubarry what we have done for the hcv treatment making them available as soon as possible to patients that needed them has profoundly transformed the pharma environment . kacy hutchison i think we ll see similar to what we saw with hiv with the big push to reach the undiagnosed we ll see that in a couple years on hcv but we want to be at the forefront to be helping people and helping systems behind the scenes understand what they can do today to be ready for tomorrow . marc aquino when i think about the work that we do i think about my children . and i think about their generation and the future for them . and i can t help but think that the work that we re doing today at gilead will leave them with a better future . exit player loading the player ... hiv aids liver diseases hematology oncology cardiovascular inflammation respiratory other therapies hiv aids gilead plays a central role in developing single tablet regimens with one pill once a day patients can take all of their medication in each dose . product info pipeline info liver diseases our liver disease programs focus on expanding treatment options for chronic hepatitis b and c. product info pipeline info hematology oncology our scientists are applying new knowledge about how cancers grow and spread to potentially enhance and improve cancer therapy . product info pipeline info cardiovascular our medicines aim to help patients with cardiovascular disease return to their daily activities and we are exploring potential new indications . product info pipeline info inflammation respiratory we research and develop treatments for serious respiratory conditions such as influenza cystic fibrosis and other diseases of the lungs . product info pipeline info other therapies gilead medicines treat severe fungal and parasitic infections and address vision loss caused by degenerative eye diseases . product info pipeline info gilead ranked 4 on change the world list fortune ranked gilead 4th among companies that have made a significant impact on the world . learn more . second quarter 2016 financial results access earnings press release webcast link and slides for gilead s second quarter 2016 results . view materials . news september 27 2016 gilead sciences and the world health organization announce five year visceral leishmaniasis collaboration about gilead senior management worldwide operations ethics business conduct business partnerships corporate history timeline research pipeline clinical trials investigator sponsored research medicines request information consumer product safety authorized distributors of record product approval timeline responsibility u.s. patient access developing world access corporate contributions policy perspectives gilead foundation news press releases events media faqs fact sheets media inquiries investors recent news corporate governance stock information financial information sec filings shareholder center annual reports email alerts investor faqs investor contacts investor disclaimer careers pipeline our values developing world access corporate contributions u.s. benefits 2009 2016 gilead . all rights reserved . terms of use privacy statements product images shown do not represent actual size .